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There is uncertainty about risk heterogeneity for venous thromboembolism (VTE) in older patients with advanced cancer and
whether patients can be stratiﬁed according to VTE risk. We performed a retrospective cohort study of the linked Medicare-
Surveillance, Epidemiology, and End Results cancer registry in older patients with advanced cancer of lung, breast, colon,
prostate, or pancreas diagnosed between 1995–1999. We used survival analysis with demographics, comorbidities, and tumor
characteristics/treatment as independent variables. Outcome was VTE diagnosed at least one month after cancer diagnosis. VTE
rate was highest in the ﬁrst year (3.4%). Compared to prostate cancer (1.4VTEs/100 person-years), there was marked variability
in VTE risk (hazard ratio (HR) for male-colon cancer 3.73 (95% CI 2.1–6.62), female-colon cancer HR 6.6 (3.83–11.38), up to
female-pancreas cancer HR 21.57 (12.21–38.09). Stage IV cancer and chemotherapy resulted in higher risk (HRs 1.75 (1.44–2.12)
and 1.31 (1.0–1.57), resp.). Stratifying the cohort by cancer type and stage using recursive partitioning analysis yielded ﬁve groups
of VTE rates (nonlocalized prostate cancer 1.4VTEs/100 person-years, to nonlocalized pancreatic cancer 17.4VTEs/100 patient-
years).Inahigh-riskpopulationwithadvancedcancer,substantialvariabilityinVTEriskexists,withnotablediﬀerencesaccording
to cancer type and stage.
Copyright © 2009 Isaac E. Hall et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The morbidity and mortality associated with venous throm-
boembolism (VTE) are substantial [1, 2]. Chronic and
debilitating sequelae include postthrombotic syndrome fol-
lowing deep vein thrombosis (DVT) or chronic pulmonary
hypertension due to pulmonary embolism (PE) [3, 4]. The
economic burden of VTE treatment is also quite high,
causing direct hospital costs of over $3000 per discharge
in a recent analysis [5]. These considerations are further
compounded for patients who develop VTE in the setting
of malignancy, as cancer further increases the risk of adverse
outcomes in patients with VTE [6–8].
While the association between thrombosis and cancer
was ﬁrst established over 100 years ago, the independent
impact of VTE on patients with cancer has been more
recently described [9]. VTE is associated with up to 40%
increased risk of death in patients with cancer, while in
certain cancer types, the mortality associated with VTE is
negligible [7]. The same analysis revealed an excess risk of
hemorrhage associated with VTE in this population as high
as 11.5%, depending on cancer type [7]. The adverse eﬀect
of VTE on patients and the morbidity of prevention and
treatment strategies reinforce the need to identify which
cancer patients are at highest risk of VTE. High-risk groups
can be monitored more closely for VTE and might be more
likely to beneﬁt from primary thromboprophylaxis.
Prior work has described substantial variability in VTE
incidence in cancer patients based on cancer type and other
characteristics. Certain groups of patients with cancer are at
no greater risk for VTE than the general population, while
other groups have very high risk [8, 10–12]. Additional work2 Journal of Cancer Epidemiology
During 2year period before cancer diagnosis:
◦ Patient enrolled in an HMO (60,771)
◦ Patient not eligible for medicare parts A
and B for any length of time (17,477)
◦ Administrative claim for VTE (3,632)
At time of cancer diagnosis:
◦ Unknown or non-advanced cancer stage
(48,987)
◦ Unknown cancer grade (11,385)
◦ Unknown or “other” race (1,220)
◦ Date of death the same as cancer diagnosis (23)
Within the same month of cancer diagnosis:
◦ Administrative claim for VTE (16,079)
Eligible population
173,788
91,908
30,293
Final cohort
14,214
Figure 1: Construction of the cohort. The eligible population included patients listed in the SEER-Medicare Database who were diagnosed
(between 1995 and 1999) with incident stage III or IV breast, lung, or colon cancer, or with nonlocalized cancer of the prostate or pancreas
at the age of 67 years or older.
has demonstrated that stage and time since diagnosis were
strongly associated with VTE risk, although important con-
founders such as cancer therapy and comorbid conditions
have not been fully investigated [6]. There also remains a
signiﬁcant knowledge gap regarding the variability of VTE
risk within the most advanced, metastatic stages of cancer.
Furthermore, it is not understood whether traditional risk
factors within the general population continue to be eﬀect
modiﬁers of VTE risk in patients with very advanced cancer.
The goal of this study was to better delineate important risk
factors within a vulnerable population traditionally believed
to be at very high risk for VTE and to assess the degree of
variability in VTE incidence across risk strata.
Trials of primary prophylaxis in the cancer patient
population have been plagued by low event rates, suggesting
that despite the diagnosis of malignancy, many of these
patients had low risk for VTE [13, 14]. There are also very
little data regarding the best way to stratify patients with
malignancy into clinically relevant subgroups based on VTE
risk. Better knowledge of risk could inform decision-making
regarding future study design and the decision to employ
thromboprophylaxis in this high-risk patient population.
We therefore performed a retrospective, population-based
cohort study of patients with ﬁve common solid tumors
that were diagnosed at advanced stages, using a nationally
representative database, to investigate the variability and
incidence of VTE and to demonstrate an eﬀective risk
stratiﬁcation approach.
2. Methods
2.1. Data Source and Study Sample. We identiﬁed the cohort
using the Surveillance, Epidemiology, and End Results
(SEER) Medicare Database, which provides detailed patient-
and tumor-level information, including socioeconomic sta-
tus of the patient, as well as stage, grade, and location of the
tumor. This population-based database collects information
from speciﬁc geographic locations and represents 26% of the
entire United States population. For those over the age of 65,
Medicareclaimsarealsoavailableandhavebeenlinkedtothe
SEER database at the patient level [15–17].
The study sample consisted of patients diagnosed with
incident stage III or IV breast, lung, or colon cancer, or
with nonlocalized cancer of the prostate or pancreas—
selected because more patients die of these cancers each
year than any others [18, 19]. The study population was
restricted to patients diagnosed with cancer from 1995
through 1999, given that outpatient treatment of VTE was
relatively uncommon during this time. In order to have two
years of prediagnosis claims, we only considered patients 67
years old or older when diagnosed with cancer, yielding an
eligible population size of 173,788 patients (Figure 1). We
excluded those who at anytime during the two years prior to
their cancer diagnosis were not eligible for Medicare Parts A
andB(17,477)orhadenrolledinanHMO(60,771).Patients
diagnosed with cancer at the time of death (23), those with
an unknown cancer grade (11,385), an unknown or non-
advanced cancer stage (48,987), and those listed as unknown
or “other” race (1,220), were also excluded. Finally, in order
to capture patients who did not have a VTE diagnosed prior
to or concomitantly with their cancer diagnosis, we excluded
patients who had an administrative claim consistent with
VTE during the two years prior to (3,632) or within the same
month of their cancer diagnosis (16,079).
2.2. Construction of Variables. We deﬁned VTE as either
DVT or PE using International Classiﬁcation of Diseases, 9th
Revision, Clinical Modiﬁcation (ICD-9-CM) claims codes:
451.1, 451.11, 451.19, 451.81, 453.2, 453.3, 453.8, 453.9,
415.1, 415.11, and 415.19. We included only those VTEsJournal of Cancer Epidemiology 3
Table 1: Sample characteristics by cancer type.
Cancer Type No. Sex, % F Median Age, yr Race, % White % High Grade % Stage IV % Surgery % Chemo % Radiation
Breast 1,789 100 76 89.6 58 37.1 80.5 34.4 37.1
Colon 1,890 57.2 75 93 27 37.4 87.3 42.2 36.4
Lung 8,102 43.4 74 91.7 78.5 50.5 18.2 38.6 53.7
Prostate 1,596 0 76 85 62.1 100 24.9 46.4 17.2
Pancreas 837 56 75 89.7 53.8 100 12.5 33.8 10.9
which were associated with a speciﬁc hospital admission.
The date of VTE was deﬁned as the date of a hospitalization
with a primary or secondary ICD-9-CM diagnosis code for
DVT or PE. VTE more than likely necessitated admission
in the vast majority of cases during our study period,
given that the ﬁrst FDA approval of a drug for outpatient
treatment of VTE did not occur until the ﬁnal year of the
study period. Thus, any VTE diagnosis code recorded in
the outpatient setting likely referred to an old VTE (prior
to cancer diagnosis), a prior VTE recorded in a system not
linked with Medicare (i.e., the Veteran’s Administration),
or was possibly a miscode. Hence, in order to enhance
speciﬁcity, only patients with inpatient VTE ICD-9 codes
were assigned a VTE diagnosis. For each patient, we created
indicators for histological grade (with grades I and II deﬁned
as “low grade” and grades III and IV deﬁned as “high
grade”), cancer speciﬁc surgery, chemotherapy, radiation
therapy, central venous catheters, and one indicator for each
condition comprising the Charlson comorbidity index, with
the exception of cancer [20]. We also included appropriate
ICD-9 codes for hip fracture and atrial ﬁbrillation as we
hypothesized that these conditions or their treatments (such
as anticoagulation) might aﬀect the risk of VTE [21–23].
These variables were obtained from hospital, outpatient,
and physician claims using previously described methods
[20, 24, 25].
2.3. Statistical Analysis. Demographic characteristics as well
as cancer grade, cancer-speciﬁc surgery, chemotherapy, and
radiation therapy were summarized for each cancer type. We
estimated incidence rates for VTE (in events per 100 person-
years) during each of the ﬁrst three years after the diagnosis
of cancer. We censored individuals at death, diagnosis of
VTE, loss of part A or B coverage, or enrollment in an
HMO. We restricted our analyses of potential predictors
of VTE to the ﬁrst year after cancer diagnosis, as VTE
incidence was the highest during this time period. We
performed bivariate analyses of gender, age, race, cancer
type, stage, grade, surgery, radiation therapy, chemotherapy,
central venous catheter use, and individual comorbidities
versus development of VTE within one year of cancer
diagnosis. We also performed a number of initial stratiﬁed
analysestobetterunderstandthebasictrendsinthedatabase.
Those variables with P values less than or equal to .2
by nonstratiﬁed, bivariate analysis were entered into a
preliminary multivariate Cox proportional hazards model,
using the same censoring strategy outlined above. Variables
with P values less than or equal to .05 were retained in the
ﬁnal model. The interaction between sex and cancer type
was assessed by a Wald test in the full model. Each cancer
type was separated by sex in the multivariate model when
appropriate (i.e., male colon, female colon, etc.) to allow all
combinationsofsexandcancertypetobeincludedinthefull
model.
We used recursive partitioning analysis (RPA) to identify
clinically distinct groups. RPA involves building binary deci-
sion trees that separate a population, based on prognostic
factors, into groups with similar outcomes (development of
VTE in this case). The strength of recursive partitioning is its
ability to identify those factors that separate groups into the
most dissimilar outcomes in a nonlinear fashion. RPA has
been used with increasing frequency to identify important
interactions between factors in diﬀerent subgroups [26].
The subgroups that result from RPA are often more homo-
geneous compared with traditional multivariate regression
models.
In our preliminary analysis, all variables that were
signiﬁcantly associated with development of VTE in the
multivariate Cox model were entered into the RPA. These
initial splitting algorithms consistently employed cancer type
andstageofmalignancy,astheﬁrstsplitting“levels.”Inorder
to derive a limited number of patient strata that are clinically
distinct and meaningful, the ﬁnal RPA splits the cohort using
only these two factors. The rate of VTE within one year of
cancer diagnosis was then calculated for each group. We then
calculated P values for the diﬀerences between groups using
Student’s t-tests.
SAS 9.1.3 (SAS Institute Inc, Cary, NC) was used to
calculate incidence rates and for survival analysis. Recursive
partitioning was performed using the STREE software
developed by Heping Zhang and Singer [27].
3. Results
Of the 14,214 patients included, the majority (8102, 57%)
had lung cancer, followed by colon (1890), breast (1789),
prostate (1596), and pancreas (837) (Table 1). The median
age was similar across all ﬁve cancer types at about 75
years old. For patients with prostate cancer, 15% were Black,
compared to 7%–10% of those with other cancers. The use
of cancer-speciﬁc therapy varied across cancer type. The vast
majority of patients with breast or colon cancer (80.5% and
87.3%, resp.) underwent surgery, while less than a quarter
of the patients with the remaining malignancies had cancer-
speciﬁc surgery.4 Journal of Cancer Epidemiology
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Figure 2: Incidence of VTE according to cancer type and time.
Incidence of VTE within each year after cancer diagnosis is shown
with error bars depicting standard deviations.
Incidence rates for VTE varied signiﬁcantly by cancer
type(Figure 2).Withinoneyearofcancerdiagnosis,prostate
cancer had the lowest rate of VTE at 1.42 per 100 person-
years, while pancreatic cancer had the highest at 17.36 per
100 person-years (P < .01; Figure 2). The other cancers had
rates ranging from approximately 4 to 6 per 100 person-
years. There was a sharp decline in incidence for all cancer
types in years two and three after diagnosis of cancer. The
overall rate (per 100-person years) decreased from 5.32
(95% CI 4.93–5.67) in the ﬁrst year to 0.97 (0.75–1.25) and
0.36 (0.20–0.60) for the second and third years, respectively
(P < .0001 for ﬁrst year rate compared with both second and
third year rates).
In bivariate analysis, VTE was signiﬁcantly related to
sex, age, cancer type, surgery, chemotherapy, and radiation
therapy (Table 2). Four of the comorbid conditions were
modestly associated with VTE, though in a protective
fashion. These included congestive heart failure (CHF: 2.5%
of those with a CHF ICD-9 code had a VTE in the ﬁrst year
after cancer diagnosis versus 3.5% of those without CHF,
P = .07), chronic obstructive pulmonary disease (COPD:
2.7% with COPD versus 3.6% without, P = .02), dementia
(<1% with dementia versus 3.5% without, P = .12), and
atrial ﬁbrillation (2.2% with atrial ﬁbrillation versus 3.5%
without, P = .04).
With prostate cancer as the reference in the ﬁnal model,
all of the other groups had increased hazard ratios (HRs) for
risk of VTE in the ﬁrst year after cancer diagnosis, ranging
from 3.73 for male-colon (95% conﬁdence interval: 2.1–
6.62) to 21.57 (12.21–38.09) for female-pancreas (Table 3).
Stage IV cancer had an increased risk of 1.75 (1.44–2.12)
when compared with stage III. The use of chemotherapy
during the ﬁrst year after diagnosis resulted in an HR of 1.31
(1.10–1.57).Increasingagetrendedtowardprotectiveagainst
VTE, with those older than 85 years showing an HR of 0.66
(0.42–1.06), though none of the age groups reached a level of
statistical signiﬁcance.
Only one of the three cancer type-sex interactions was
signiﬁcant (with prostate cancer as the reference group); the
risk for VTE was higher for women compared with men
with colon cancer (female HR 6.6 (3.83–11.38), male HR
3.73 (2.1–6.62), P = .02 for sex∗colon cancer interaction).
The VTE risk was similar for both sexes among patients with
pancreatic or lung cancer.
RPA analysis resulted in ﬁve distinct VTE risk groups
(Figure 3). Initial partitioning separated nonlocalized
prostate cancer from the cohort with a VTE rate of 1.4 per
100 person-years. Stage III cancers were separated from
the remaining cohort in the second split. This group was
further divided by lung cancer with a VTE rate of 5.2 per
100 person-years, leaving breast and colon cancer, with
a combined VTE rate of 4.0 per 100 person-years. The
last splitting procedure separated nonlocalized pancreatic
cancer, with the highest rate of 17.4, and leaving stage IV
cancer of the lung, breast, and colon with a combined rate of
7.2 VTEs per 100 person-years.
4. Discussion
Patients with advanced cancer are at increased risk for VTE
[6, 7, 28]. We have added three speciﬁc ﬁndings to this
body of knowledge using a population-based cohort of older
patients with ﬁve common, advanced solid tumors. (1) Even
in advanced cancer, there is signiﬁcant heterogeneity in the
incidence and risk for VTE within the ﬁrst years after cancer
diagnosis, based on cancer type and stage. (2) Increasing
stage and the use of chemotherapy elevate VTE risk in
advanced cancer, while other traditional risk factors are not
signiﬁcant in this population. (3) Eﬀective risk stratiﬁcation
is possible within a population with advanced malignancy
usingrecursivepartitioning.Thisallowsfortheidentiﬁcation
of those patients with highest VTE risk, indicating who
should be most closely monitored.
Several mechanisms lead to an increased risk of VTE
in the cancer patient population. The signiﬁcant variability
in VTE incidence and risk demonstrated here is likely
related to nonuniform distribution of these mechanisms
between cancer types, stages, and the use of chemotherapies.
Generalized causes include more frequent use of central
venous catheters, decreased mobility, and more frequent
acute medical illnesses in the oncology population than
in the general population. Other malignancy-associated
mechanisms include direct vascular invasion and exter-
nal compression by tumor, endothelial cell injury from
chemotherapy, cancer cell production of tissue factor and
factor X activator, platelet accumulation and activation, and
increased levels of acute-phase reactants like von Willebrand
factor and factor VIII due to cancer-related inﬂammation
[29–31].
The variability in VTE risk shown in the current study
bolsters previous work on VTE predictors in patients with
cancer. Chew et al. demonstrated a high incidence of throm-
boembolism in metastatic cancer of the pancreas, stomach,Journal of Cancer Epidemiology 5
Table 2: Patient and cancer characteristics and rate of venous thromboembolism within 1 year after cancer diagnosis.
Predictor Total VTE % (95% CI) P value
Male 7,579 219 2.9 (2.51–3.27)
Female 6,635 270 4.1 (3.59–4.55) <.01
Age 67–69 2,427 107 4.4 (3.59–5.23)
Age 70–74 4,497 184 4.1 (3.51–4.67)
Age 75–79 3,791 119 3.1 (2.58–3.7)
Age 80–84 2,282 56 2.5 (1.82–3.08)
Age 85+ 1,217 23 1.9 (1.12–2.66) <.01
White 12,899 439 3.4 (3.09–3.71)
Black 1,315 50 3.8 (2.77–4.83) .45
Breast cancer 1,789 72 4.0 (3.11–4.93)
Colon cancer 1,890 74 3.9 (3.05–4.79)
Lung cancer 8,102 273 3.4 (2.98–3.76)
Prostate cancer 1,596 20 1.3 (0.7–1.8)
Pancreatic cancer 837 50 6.0 (4.36–7.58) <.01
Stage 3 6,322 221 3.5 (3.05–3.95)
Stage 4 7,892 268 3.4 (3–3.8) .75
Grade 1 or 2 4,867 171 3.5 (2.99–4.03)
Grade 3 or 4 9,347 318 3.4 (3.03–3.77) .73
Surgery 5,065 204 4.0 (3.49–4.57) <.01
Chemotherapy 5,559 260 4.7 (4.12–5.24) <.01
Radiation therapy 6,069 251 4.1 (3.64–4.64) <.01
MI 384 11 2.9 (1.19–4.53) .53
CHF 1,059 26 2.5 (1.53–3.39) .07
PVD 517 15 2.9 (1.45–4.35) .49
CVD 687 19 2.8 (1.53–4) .32
COPD 2,652 71 2.7 (2.07–3.29) .02
Dementia 117 <5 0.9 (0–2.51) .12
Diabetes 1,689 50 3.0 (2.15–3.77) .25
Chronic Kidney Disease 160 <5 1.9 (0–3.98) .28
Ulcers 213 6 2.8 (0.6–5.04) .62
Rheumatologic disease 264 9 3.4 (1.22–5.6) .98
Hip fracture 395 12 3.0 (1.35–4.73) .66
Atrial Fibrillation 896 20 2.2 (1.26–3.2) .04
Obesity 103 5 4.9 (0.7–9) .43
Bivariate analysis of cancer and patient characteristics on development of VTE. The following comorbid conditions were removed because of prevalences
<100: paralysis, cirrhodites, AIDS, and central venous catheter. Myocardial infarction: MI; congestive heart failure: CHF; peripheral vascular disease: PVD;
cerebrovascular disease: CVD; chronic obstructive pulmonary disease: COPD.
bladder, uterus, kidney, and lung with the highest incidence
of VTE occurring in the ﬁrst year after cancer diagnosis [6].
Sallah et al. noted that chemotherapy, advanced malignancy,
and tumors of the kidney, pancreas, stomach, and brain were
independently associated with VTE [32]. Blom et al. showed
a high incidence of VTE in cancers of the bone, ovary, brain,
and pancreas as well as higher VTE risk with distant metas-
tases, chemotherapy, and hormone therapy [11]. As with our
ﬁndings,thelatterstudydidnotrevealstrongassociationsfor
VTE with radiotherapy or surgery. Hormonal therapy was
not diﬀerentiated from chemotherapy in our database. The
lower risk associated with years two and three was likely due
to the fact that the most aggressive cancers lead to increased
mortality in addition to increased risk of VTE, as evident by
thelargedecrementintotalpatientswitheachsuccessiveyear
(Figure 2).
The absolute risk of VTE seen in this cohort is quite
high in comparison to the general population. Using two
population-based cohorts of patients at least 45 years old, in
which less than 8% had cancer, the LITE study demonstrated
a higher rate of VTE in men than women over the age of
74–5.5 versus 2.7 per 1000 person-years [33]. These rates
are much lower than our reference rate of 1.4 VTEs per
100 person-years (or 14 per 1000 person-years) in patients
with nonlocalized prostate cancer, with all other groups
demonstrating even higher rates.6 Journal of Cancer Epidemiology
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(n = 14,214)
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Figure 3: Recursive partitioning ﬁnal analysis. Cancer of the prostate and pancreas is “nonlocalized.” Rates are number of VTEs per 100
person-years (95% conﬁdence interval).
Table 3: Factors associated with developing a VTE within one year
of cancer diagnosis: ﬁnal cox proportional hazards model.
Variable Hazard 95% CI P value
Prostate 1.0
Breast 4.86 2.93 8.08 <.01
Female colon 6.60 3.83 11.38 <.01
Male colon 3.73 2.10 6.62 <.01
Female lung 7.57 4.67 12.26 <.01
Male lung 7.64 4.73 12.34 <.01
Female pancreas 21.57 12.21 38.09 <.01
Male pancreas 17.68 9.48 32.95 <.01
Stage 3 1.0
Stage 4 1.75 1.44 2.12 <.01
Chemotherapy 1.31 1.10 1.57 <.01
The higher risk for VTE in female compared with
male colon cancer patients was unanticipated. Hormonal
diﬀerences could play a signiﬁcant role, but this is unlikely
given the mean age in this study. There was also no
diﬀerence in cancer-speciﬁc treatment between the sexes in
thisdatabase.Onestudyhasshownthathospitalizedmenare
21% more likely than women to receive DVT prophylaxis,
but it is unlikely that many men were given outpatient
prophylaxis preferentially over women in this cohort [34]. A
large database study by Khorana et al. demonstrated overall
increased risk of VTE associated with female gender with
an adjusted odds ratio of 1.14 (95% CI 1.12 to 1.16) [35].
Conversely,Kr¨ ogeretal.foundnodiﬀerencebasedongender
in their study of VTE risk factors speciﬁc to cancer patients
[36]. Our ﬁnding of gender diﬀerences in VTE risk must be
interpreted with caution as three gender-cancer comparisons
were made. A P value of .02 for the interaction term is of
marginal signiﬁcance, and additional studies are needed to
conﬁrm these results.
Although increasing age, CHF, COPD, dementia, and
atrialﬁbrillationwereprotectiveinbivariateanalysis,allwere
nonsigniﬁcant in multivariate analysis. Discordant results on
the risk associated with age were shown in the studies by
Khorana et al. [35] (adjusted odds ratio of 1.08 (1.05–1.11)
for age >65) and Kr¨ oger et al. [36] (no signiﬁcant diﬀerence
with age). Atrial ﬁbrillation could appear protective because
of concomitant use of anticoagulation. Older age, CHF, and
COPD have been shown to increase the risk for VTE in
the general population [37–39], and Chew and colleagues
have demonstrated variable increased risk associated with
increasing comorbidity in several diﬀerent cancer popula-
tions [40–42]. Comorbidity codes may not be complete
for every patient in the SEER-Medicare Database, which
couldhaveinﬂuencedourﬁndings.Clinically,however,there
may also be a real a hesitation to hospitalize older patients
with both advanced cancer and other severe comorbidities
who then develop VTE. As such, patients with more
aggressive tumors may be less likely to undergo diagnostic
evaluation for potential VTE if they face an extremely short
life expectancy from their advanced cancer. Families may
be more apt to consider end-of-life plans during these
situations.
There are some limitations to consider. These are
retrospective data using Medicare claims (ICD-9 coded)
for the diagnosis of VTE and other comorbidities. Others
have validated the accuracy of this approach, but many
cases of VTE were likely missed or miscoded [6, 10, 43].
As a result, these VTE rates likely underestimate the true
burden of disease in the cancer patient population. Our
database also lacked speciﬁc laboratory information, such as
platelet count, and does not specify which chemotherapeutic
agents and doses were used. Importantly, the cohort was
predominantly Caucasian. Given this fact, and the need
to restrict the cohort to those at least 67 years old in
order to appropriately use the SEER-Medicare Database,
our results apply to older patients with cancer and are
not necessarily generalizable to a more racially diverse and
younger population.Journal of Cancer Epidemiology 7
Only VTE claims associated with hospital admissions
were considered to focus on the most clinically relevant and
acute cases. Earlier studies demonstrated the eﬀectiveness
of outpatient VTE treatment using low-molecular-weight
heparin (LMWH), but the ﬁrst LMWH approved for this
indication, enoxaparin, was toward the end of our study
period in December, 1998 [44–46]. We found no studies that
speciﬁcally evaluated national trends in outpatient treatment
of VTE prior to 2000. While several studies assessed the
utility of outpatient management of VTE toward the end
of our study period [45, 47–49], there was disagreement in
the literature about appropriate eligibility criteria for initial
outpatient treatment, and outpatient treatment of PE was
considered by some to be contraindicated [50, 51]. Given
this and the absence of data describing large numbers of
advanced cancer patients with incident VTE being treated as
outpatients, the idea that the vast majority of these patients
would have been admitted for standard-of-care treatment is
valid.
Lastly, we have not validated the recursive partitioning
approach used to stratify this cohort into clinically relevant
risk groups. Our purpose for using RPA was to demonstrate
that eﬀective VTE risk stratiﬁcation is potentially feasible
even in this high-risk group with metastatic disease. As
demonstrated by Khorana et al. using a multivariate model,
stratiﬁcation tools should undergo validation with separate
data sets prior to implementation [52].
The combined one-year cumulative incidence of VTE in
this study was 3.4%. This is similar to rates seen in controls
for trials of both LMWH and low-intensity coumadin as
primary prophylaxis in patients with cancer, 3.3% and
4.4%, respectively [13, 53]. In high-risk medical patients
without cancer, the PREVENT, ARTEMIS, and MEDENOX
placebo-controlled trials revealed decrements in VTE rates
with thromboprophylaxis from 5.0% to 2.8%, 10.5% to
5.6%, and 14.9% to 5.5%, respectively [54–56]. Higher
baseline rates in the latter two trials are explained by their
use of routine screening with Doppler ultrasound and/or
venography. Without this sensitive screening method, we
have demonstrated VTE rates in advanced cancer other than
prostate ranging from 4.0 to 17.4 VTEs per 100 person-
years. Future research should focus on the demonstration of
VTE risk reduction in ambulatory, nonhospitalized cancer
patients at highest risk.
One study that attempted to address VTE reduction
in high risk cancer patients was the FAMOUS trial, which
evaluated 374 patients with stages III and IV cancers
of the breast, lung, gastrointestinal tract, pancreas, liver,
genitourinary tract, ovary, and uterus [13]. No statistically
signiﬁcant survival beneﬁt was noted with LMWH versus
placebo after one year. A nonsigniﬁcant decrease in VTE rate
from 3.3% to 2.4% was demonstrated, though diagnostic
method was not speciﬁed and VTE rate was not a primary
outcome. As a result, guidelines do not recommend primary
VTE prophylaxis for nonhospitalized cancer patients in the
absence of other risk factors [28]. A one-year event rate of
3.3% in the placebo group of the FAMOUS trial appears low
compared to rates of 4.0 to17.4 per 100 person-years as seen
in the highest-risk groups of the current study. A signiﬁcant
diﬀerence in event rates may be detected in future trials
if the study groups are more homogeneously high-risk for
VTE. As a case in point, a placebo-controlled trial using
low-intensity coumadin in 311 women with stage IV breast
cancer undergoing chemotherapy for a mean duration of six
months did demonstrate a signiﬁcant decrease in VTE rate
from 4.4% to 0.7%, which was the primary outcome for the
trial [53]. The conclusion that VTE prophylaxis is relatively
safe and eﬀective in this group of patients was justiﬁed by
the reduction in thrombosis rate, despite the fact that the
secondary outcome of overall mortality reduction was not
demonstrated within the follow-up period.
Our ﬁndings give additional insight about VTE risk in
patients with cancer. We have shown that even in patients
with advanced solid tumors, there is substantial variability
in VTE risk. These data demonstrate that ambulatory
cancer patients can be stratiﬁed into groups with VTE
rates similar to nonsurgical, acutely ill-hospitalized patients.
Additional trials are needed in oncology patient groups at
the highest risk to determine if thromboprophylaxis is as
eﬀective as it is in acute medical illness. Most importantly,
patients with advanced (stage IV) cancer of the lung, breast,
colon, or “nonlocalized” pancreatic cancer as well as those
patients undergoing chemotherapy should have close clinical
monitoring for the development of VTE.
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